Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.4.2.30: NAD+ ADP-ribosyltransferase

This is an abbreviated version!
For detailed information about NAD+ ADP-ribosyltransferase, go to the full flat file.

Word Map on EC 2.4.2.30

Reaction

NAD+
+
(ADP-D-ribosyl)n-acceptor
=
nicotinamide
 +
(ADP-D-ribosyl)n+1-acceptor
 +
H+

Synonyms

(adenosine diphosphoribose)transferase, nicotinamide adenine dinucleotide-protein, 193-kDa vault protein , 2,3,7,8-tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase, adenosine diphosphate ribosyltransferase, ADP-ribosylating thermozyme, ADP-ribosyltransferase, ADP-ribosyltransferase (polymerizing), ADP-ribosyltransferase 3, ADP-ribosyltransferase C3cer, ADP-ribosyltransferase-1, ADPr, ADPRT, ADPRT , ART, ART1, ARTC2.2, ARTD10, ARTD10/PARP10, ARTD11, ARTD14, ARTD3, ARTD7/PARP15, ARTD8, asparagine-specific ADP-ribosyltransferase, B aggressive lymphoma protein 2, C3 exoenzyme, C3-like toxin, C3larvin toxin, C3lim, CRM66, diphtheria toxin-like ADP-ribosyltranferase, ecto-ADP-ribosyltransferase, ecto-ADP-ribosyltransferase 2.2, ecto-ADP-ribosyltransferase ART2.2, EspJ, Exo53, exoenzyme C3, exoenzyme S, exoenzyme T, ExoS, ExoT, exotoxin-S, mART, ModA, ModB, mono ADP-ribosyltransferase, mono(ADP-ribosyl) transferase, mono-ADP-ribosyl transferase C3, mono-ADP-ribosyltransferase, More, msPARP , NAD(+) ADP-ribosyltransferase , NAD+:ADP-ribosyltransferase (polymerizing), NAD-dependent ADP-ribosyltransferase, NAD-protein ADP-ribosyltransferase, NarE, pADPRT, PAR polymerase, PARP, PARP , PARP-1, PARP-7, PARP-related/IalphaI-related H5/proline-rich , PARP1, PARP10, PARP11, PARP14, PARP3, PARPss, pertussis toxin, PH5P , poly (ADP-ribose) polymerase, poly (ADP-ribose) polymerase-1, poly(ADP-ribose) polymerase, poly(ADP-ribose) polymerase family member 11, poly(ADP-ribose) polymerase-1, poly(ADP-ribose) polymerase-11, poly(ADP-ribose) polymerase-like enzyme, poly(ADP-ribose) synthase, poly(ADP-ribose) transferase, poly(ADP-ribosyl)transferase, poly[ADP-ribose] synthetase , PTx, PtxS1, scabin, TANK1, TANK1 , TANK2 , tankyrase I, Tankyrase-like protein , Tankyrase-related protein , TbSIR2RP1, TiPARP, TNKS-1, TRF1-interacting ankyrin-related ADP-ribose polymerase, TRF1-interacting ankyrin-related ADP-ribose polymerase , TTS-ExoS, type III-secreted toxin, VahC, VPARP , vsdc, YART

ECTree

     2 Transferases
         2.4 Glycosyltransferases
             2.4.2 Pentosyltransferases
                2.4.2.30 NAD+ ADP-ribosyltransferase

Inhibitors

Inhibitors on EC 2.4.2.30 - NAD+ ADP-ribosyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1E,4E)-1,5-di(pyridin-3-yl)penta-1,4-dien-3-one
i.e. NSC149286
(2S)-2-[[3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoyl]amino]-3-phenylpropanamide
-
(beta,beta-dimethylacryl)shikonin
64% inhibition at 0.01 mM; 64% inhibition at 0.01 mM
0469-0796
-
restores yeast growth after treatment with ExoS
1(2H)-phthalazinone
-
IC50: 0.012 mM
1,2-benzopyrone
-
IC50: 2.8 mM
1,3-benzodiazine
-
IC50: 2.0 mM
1,3-dihydroxynaphthalene
-
IC50: 1.3 mM
1,4-benzoquinone
-
IC50: 0.4 mM
1,4-naphthalenedione
-
IC50: 0.25 mM
1,5-dihydroxyisoquinoline
-
IC50: 0.00039 mM
1,8-naphthalimide
-
IC50: 0.0014 mM
1-hydroxy-2-methyl-4-aminonaphthalene
-
IC50: 1.3 mM
1-hydroxyisoquinoline
-
IC50: 0.007 mM
1-Indanone
-
IC50: 0.81 mM
1-methylnicotinamide chloride
2,3-benzodiazine
-
IC50: 0.15 mM
2,3-dichloro-1,4-naphthoquinone
-
IC50: 0.26 mM
2,3-dihydro-1,4-phthalazinedione
-
IC50: 0.03 mM
2,3-dihydro-5-hydroxy-1,4-phthalazinedione
-
0.001 mM, 95% inhibition of the 116000 Da enzyme
2,4(1H,3H)-quinazolinedione
-
IC50: 0.0081 mM
2,6-difluorobenzamide
-
IC50: 0.18 mM
2-(3-hydroxypropyl)-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one
-
-
2-(3-hydroxypropyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-(4-[4-[(2,4-dimethoxyphenyl)amino]quinazolin-2-yl]piperazin-1-yl)ethanol
-
2-acetamidobenzamide
-
IC50: 1.0 mM
2-amino-3-chloro-1,4-naphthoquinone
-
IC50: 0.82 mM
2-Aminobenzamide
2-bromobenzamide
-
IC50: 2.9 mM
2-chlorobenzamide
-
IC50: 1.0 mM
2-fluorobenzamide
-
IC50: 0.12 mM
2-Hydroxy-1,4-naphthoquinone
-
IC50: 0.33 mM
2-hydroxybenzamide
-
IC50: 0.82 mM
2-mercapto-4(3H)-quinazolinone
-
IC50: 0.044 mM
2-Methoxybenzamide
-
IC50: 0.2 mM
2-methyl-1,4-benzopyrone
-
IC50: 0.045 mM
2-methyl-1,4-naphthoquinone
-
IC50: 0.42 mM
2-methyl-3-phytyl-1,4-naphthoquinone
-
IC50: 0.52 mM
2-methyl-4(3H)-quinazolinone
-
IC50: 0.056 mM
2-methylbenzamide
-
IC50: 1.5 mM
2-methylchromone
-
IC50: 0.045 mM
2-nitro-6(5H)-phenanthridione
-
IC50: 0.00035 mM
2-phenylchromone
-
IC50: 0.022 mM
2-trichloromethyl-4(3H)-quinazolinone
-
IC50: 2.2 mM
2-[[3-(dimethylamino)-2-oxopropyl]amino]-5,6-dihydrophenanthridin-6-one
potent inhibitor
2H-benz[c]isoquinolin-1-one
-
IC50: 0.0003 mM
2H-benz[de]isoquinoline-1,3-dione
-
IC50: 0.0014 mM
3,4-dihydro-1(2H)-naphthalenone
-
IC50: 0.31 mM
3,5-dibromosalicylamide
-
IC50: 0.56 mM
3,5-dimethoxybenzamide
-
IC50: 1.2 mM
3,5-dinitrobenzamide
-
IC50: 2.5 mM
3-(4-methoxy-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)propanoic acid
-
-
3-(4-oxo-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-2-yl)propanoic acid
-
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1R)-1-(pyridin-2-yl)ethyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1R)-1-phenylethyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1S)-1-(pyridin-2-yl)ethyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1S)-1-phenylethyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1S)-1-phenylpropyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[1-(4-sulfamoylphenyl)ethyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[1-(pyridin-2-yl)ethyl]propanamide
-
3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid
-
-
3-(4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)propanoic acid
-
inhibitor with micromolar potency
3-(N,N-dimethylamino)benzamide
-
IC50: 0.12 mM
3-Acetamidobenzamide
-
IC50: 0.012 mM
3-acetamidosalicylamide
-
IC50: 2.0 mM
3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole
-
i.e. Trp-P-1, 94% inhibition at 5 mM, IC50: 0.22 mM
3-amino-1-methyl-5H-pyrido[4,3-b]indole
-
i.e. Trp-P-2, 34% activation at 1 mM, 7% inhibition at 5 mM, IC50: 2.2 mM
3-aminobenzamide
3-aminobenzoic acid
-
1 mM, 12% inhibition
3-Aminophthalhydrazide
3-bromobenzamide
-
IC50: 0.055 mM
3-Chlorobenzamide
-
IC50: 0.22 mM
3-Fluorobenzamide
-
IC50: 0.2 mM
3-Guanidinobenzamide
-
0.1 mM, 71% inhibition of the 116000 Da enzyme
3-Hydroxybenzamide
3-isobutyl-1-methylxanthine
-
IC50: 3.1 mM
3-Methoxybenzamide
3-Methylbenzamide
-
IC50: 0.19 mM
3-nitrobenzamide
-
IC50: 0.16 mM
3-nitrophthalhydrazide
-
IC50: 0.072 mM
3-nitrosalicylamide
-
IC50: 1.6 mM
4,4'-(methylmino)dibenzamide
26% inhibition at 0.01 mM
4,4'-thiodibenzamide
30% inhibition at 0.01 mM
4,5,7,9-tetrahydro-2H-purine-2,8(3H)-dithione
i.e. NSC29193
4,8-dihydroxy-2-quinolinecarboxylic acid
-
IC50: 0.19 mM
4-(2-fluorophenoxy)benzamide
-
4-(2-phenoxyethoxy)benzamide
-
4-(4-aminophenoxy)benzamide
-
4-(4-carbamoylphenoxy)benzoic acid
-
4-(4-formylphenoxy)benzamide
-
4-(4-hydroxyphenoxy)benzamide
-
4-(4-methoxyphenoxy)benzamide
-
4-(4-nitrobenzoyl)benzamide
24% inhibition at 0.01 mM
4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid
-
-
4-(benzyloxy)benzamide
-
4-(pyridin-2-yloxy)benzamide
49% inhibition at 0.01 mM
4-amino-1,8-naphthalimide
-
IC50: 0.00018 mM
4-Aminobenzamide
4-aminophthalhydrazide
-
IC50: 0.29 mM
4-bromobenzamide
-
IC50: 2.2 mM
4-butoxybenzamide
-
4-carbamoylphenyl benzoate
-
4-chlorobenzamide
-
IC50: 0.3 mM
4-chromanone
-
IC50: 0.72 mM
4-ethoxybenzamide
-
4-fluorobenzamide
-
IC50: 0.2 mM
4-hydroxy-2-methylquinoline
-
IC50: 0.074 mM
4-hydroxy-2-quinolinecarboxylic acid
-
IC50: 0.67 mM
4-hydroxybenzamide
4-Hydroxycoumarin
-
IC50: 0.57 mM
4-hydroxypyridine
-
IC50: 2.3 mM
4-hydroxyquinazoline
-
IC50: 0.0095 mM
4-hydroxyquinoline
-
IC50: 0.08 mM
4-methoxybenzamide
4-methylbenzamide
-
IC50: 1.8 mM
4-nitro-7-[(1-oxo-1lambda(5)-pyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole
i.e. NSC228155
4-nitrophthalhydrazide
-
IC50: 0.51 mM
4-phenoxybenzamide
-
4-[(2-bromophenyl)methoxy]benzamide
-
4-[(2-fluorophenyl)methoxy]benzamide
-
4-[(3,5-dimethylphenyl)methoxy]benzamide
-
4-[(3-bromophenyl)methoxy]benzamide
-
4-[(3-fluorophenyl)methoxy]benzamide
-
4-[(4-cyanophenyl)thio]benzamide
16% inhibition at 0.01 mM
4-[(4-fluorophenyl)methoxy]benzamide
-
4-[(4-methylphenyl)methoxy]benzamide
-
4-[(naphthalen-1-yl)methoxy]benzamide
-
4-[(propan-2-yl)oxy]benzamide
-
4-[(pyridin-2-yl)methoxy]benzamide
-
4-[1-[4-(propan-2-yl)phenyl]ethoxy]benzamide
16% inhibition at 0.01 mM
4-[4-(1-aminoethenyl)phenoxy]benzamide
4-[8-fluoro-6-oxo-1H,2H,3H,4H,5H,6H-benzo[c]1,6-naphthyridin-2-yl]butanoic acid
-
4-[[4-(aminocarbonyl)benzyl]oxy]benzamide
-
4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]-N,N-dimethylpiperidine-1-carboxamide
-
activates in presence of Mg2+, inhibits in absence of Mg2+
4296-1011
-
restores yeast growth after treatment with ExoS
5-acetamidosalicylamide
-
IC50: 0.045 mM
5-aminosalicylamide
-
IC50: 0.1 mM
5-bromodeoxyuridine
-
IC50: 0.015 mM
5-Bromouracil
-
IC50: 0.16 mM
5-Bromouridine
-
IC50: 0.21 mM
5-chlorosalicylamide
-
IC50: 0.19 mM
5-Chlorouracil
-
IC50: 0.27 mM
5-hydroxy-1,4-naphthoquinone
-
IC50: 0.25 mM
5-Hydroxy-2-methyl-1,4-naphthoquinone
-
IC50: 0.7 mM
5-Iodouracil
-
IC50: 0.071 mM
5-iodouridine
-
IC50: 0.043 mM
5-Methylnicotinamide
5-methyluracil
-
IC50: 0.29 mM
5-Nitrouracil
-
IC50: 0.43 mM
6(5H)-phenanthridinone
-
IC50: 0.0003 mM
6-aminocoumarin
-
IC50: 0.85 mM
6-aminonicotinamide
-
IC50: 1.1 mM
8-acetamidocarsalam
-
IC50: 1.4 mM
8-fluoro-2-[3-(piperidin-1-yl)propanesulfonyl]-1H,2H,3H,4H,5H,6H-benzo[c]1,6-naphthyridin-6-one
-
8-fluoro-2-[3-(piperidin-1-yl)propyl]-1H,2H,3H,4H,5H,6H-benzo[c]1,6-naphthyridin-6-one
-
8-Methylnicotinamide
-
IC50: 7.8 mM
acetophenone
-
IC50: 2.3 mM
ADP-D-ribose
-
5 mM, remaining activity: 7.3%
AG14361
-
-
all-trans-retinal
-
IC50: 0.45 mM
Alpha-NAD+
-
0.5 mM, 40% inhibition of the 116000 Da enzyme, 44% inhibition of the 90000 Da enzyme
alpha-picolinamide
-
IC50: 0.25 mM
AMP
-
1 mM, remaining activity: 3.6%
arachidonic acid
-
-
Benzamide
benzoyleneurea
-
IC50: 0.0081 mM
bergapten
69% inhibition at 0.01 mM; 69% inhibition at 0.01 mM
Caffeine
carbonylsalicylamide
-
IC50: 0.46 mM
carsalam
-
5 mM, 88% inhibition in presence of Mg2+, 68% inhibition in absence of Mg2+
Chlorthenoxazin
-
IC50: 0.0085 mM
chromone-2-carboxylic acid
-
IC50: 0.56 mM
Cu2+
-
-
cyclohexanecarboxamide
-
IC50: 0.62 mM
deoxyshikonin
67% inhibition at 0.01 mM; 67% inhibition at 0.01 mM
diosmin
-
restores yeast growth after treatment with ExoS
DMSO
at 2% (v/v) DMSO isoform ARTD10 loses more than half of its activity; at 2% (v/v) DMSO isoform ARTD7 loses its activity completely
E216-5303
-
restores yeast growth after treatment with ExoS
EB-47
i.e. 5'-deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine dihydrochloride; i.e. 5'-deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine dihydrochloride
EDTA
-
5 mM, 41% inhibition in presence of Mg2+, 2% inhibition in absence of Mg2+
embelin
57% inhibition at 0.01 mM; 57% inhibition at 0.01 mM
everninic acid
-
restores yeast growth after treatment with ExoS
exosin
-
a small molecule inhibitor, that modulates ExoS ADP-ribosyltransferase activity in vitro, suggesting the inhibition is direct. Exosin and two of its analogues display a significant protective effect against Pseudomonas infection in vivo, competitive against NAD+
flavokawain B
-
restores yeast growth after treatment with ExoS
flavone
-
IC50: 0.022 mM
gambogic acid
75% inhibition at 0.01 mM; 75% inhibition at 0.01 mM
gamma-linolenic acid
-
IC50: 0.12 mM
gossypol
75% inhibition at 0.01 mM; 75% inhibition at 0.01 mM
GTP(gammaS)
-
in presence of Mg2+
Hg2+
-
-
hypoxanthine
-
IC50: 1.7 mM
Isonicotinamide
-
IC50: 0.99 mM
Isonicotinate hydrazide
-
IC50: 4.8 MM
Isoquinoline
-
5 mM, 47% inhibition in presence of Mg2+, 34% inhibition in absence of Mg2+
linoleic acid
-
IC50: 0.048 mM
linolenic acid
-
IC50: 0.11 mM
m-acetamidoacetophenone
-
IC50: 0.93 mM
m-aminoacetophenone
-
IC50: 1.9 mM
m-hydroxyacetophenone
-
IC50: 0.6 mM
m-phthalamide
-
IC50: 0.05 mM
menadione
55% inhibition at 0.01 mM; 55% inhibition at 0.01 mM
menadione sodium bisulfite
-
IC50: 0.72 mM
methyl (2S)-2-[[3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoyl]amino]-3-phenylpropanoate
-
myricetin
78% inhibition at 0.01 mM; 78% inhibition at 0.01 mM
N-(2-chloroethyl)1,8-naphthalamide
-
IC50: above 1.8 mM
N-(6-oxo-5,6-dihydrophenanthrolin-2-yl)-(N,N-dimethylamino)acetamide
-
0.1 mM, remaining activity: 36.2%
N-(acridin-9-yl)-4-nitrobenzamide
-
N-hydroxynaphthalimide sodium salt
-
IC50: 0.45 mM
N-[(1R)-2,3-dihydro-1H-inden-1-yl]-3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanamide
-
N-[(1S)-2,3-dihydro-1H-inden-1-yl]-3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanamide
-
N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanamide
-
N-[(2S)-1-hydroxybutan-2-yl]-3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanamide
-
N-[(2S)-1-hydroxypropan-2-yl]-3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanamide
-
N-[1-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanamide
-
N-[2-oxo-4-(phenylamino)-3,8a-dihydro-2H-chromen-3-yl]acetamide
-
N-[[1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-3-yl]methyl]methanesulfonamide
-
nicotinamide
norharman
-
IC50: 4.7 mM
novobiocin
-
IC50: 2.2 mM, 5 mM, 90% inhibition in presence of Mg2+, 59% inhibition in absence of Mg2+
olaparib
oleic acid
-
IC50: 0.082 mM
palmitoleic acid
-
IC50: 0.095 mM
PCMB
-
complete
phenanthridinone
-
5 mM, remaining activity: 35.1%
phenantridinone
i.e. 6(5H)-phenantridinone; i.e. 6(5H)-phenantridinone
phthalamide
-
IC50: 1.0 mM
Phthalazine
-
5 mM, 91% inhibition in presence of Mg2+, 79% inhibition in absence of Mg2+
PJ34
-
potent PARP inhibitor
Plumbagin
67% inhibition at 0.01 mM; 67% inhibition at 0.01 mM
Pyrazinamide
-
IC50: 0.13 mM
Quinazoline
-
5 mM, 63% inhibition in presence of Mg2+, 50% inhibition in absence of Mg2+
rabusertib
-
-
reserpine
-
IC50: 0.79 mM
rucaparib
-
-
Theobromine
theophylline
thiobenzamide
-
IC50: 0.62 mM
Thionicotinamide
-
IC50: 1.8 mM
thymidine
TIQ-A
i.e. 4H-thieno[2,3-c]isoquinolin-5-one; i.e. 4H-thieno[2,3-c]isoquinolin-5-one
trans-decahydro-1-naphthalenone
-
IC50: 4.3 mM
trimethylpsoralen
61% inhibition at 0.01 mM; 61% inhibition at 0.01 mM
VE822
-
-
veliparib
-
-
vitamin K1
-
IC50: 0.0019 mM
vitamin K3
-
IC50: 0.42 mM
xanthurenic acid
-
5 mM, 88% inhibition in presence of Mg2+, 65% inhibition in absence of Mg2+
Zinc acetate
-
0.1 mM, remaining activity: 0.5%
additional information
-